About
Antibody therapeutics have become a major component of modern oncology and continuous innovations are rapidly reshaping the field. Advances in antibody discovery and engineering, immune engagement, targeted delivery, molecular imaging and analytical technologies are creating new opportunities to better characterize tumors and develop more precise therapeutic strategies.
The Antibody Innovation Summit 2026 is built around one central question: how can emerging antibody technologies address unmet clinical needs to reach meaningful patient impact?
Under the theme “Technologies with Patient Impact: The Latest Advances in Antibody Innovation,” this summit bridges clinical needs with advances in antibody research and therapeutic development. Clinicians, academic researchers and industry experts will share their perspectives on emerging approaches, their current limitations and the conditions required to drive them closer to clinical application.
Join biotechnology companies, CROs, technology providers and scientific and medical experts for a full day of expert talks, case studies and a panel discussion on September 22, 2026, at The Hive – PSCC, Villejuif.
The event is free to attend, but registration is required due to limited capacity.
Our Speakers
Agenda
•
08:30 – 09:00
Registration, Coffee & Networking
Check in, get breakfast, and connect with your peers before the Antibody Innovation begins.
Check in, get breakfast, and connect with your peers before the Antibody Innovation begins.
•
09:00 – 09:10
Welcome & Opening Remarks
Catherine Laporte, PSCC
Catherine Laporte, PSCC
•
09:10 – 09:45
Principles of therapeutic antibodies in oncology
Aurélien Marabelle, Physician-Scientist, Gustave Roussy
Biologics have revolutionized oncology practice. However their design and mode of action remain poorly understood by most clinicians and scientists. Prof. Marabelle will review the fundamental principles that drive efficacy of tumor targeting and immune targeting antibodies in oncology.
Aurélien Marabelle, Physician-Scientist, Gustave Roussy
Biologics have revolutionized oncology practice. However their design and mode of action remain poorly understood by most clinicians and scientists. Prof. Marabelle will review the fundamental principles that drive efficacy of tumor targeting and immune targeting antibodies in oncology.
•
09:45 – 10:20
Tiny but Mighty ! Single-Domain Antibodies for Cancer Imaging and Immunotherapies
Patrick Chames, Team Leader, CRCM
The talk will highlight some examples of the use of synthetic biology based on single domain antibodies with a focus on antibody based cancer immunotherapies.
Patrick Chames, Team Leader, CRCM
The talk will highlight some examples of the use of synthetic biology based on single domain antibodies with a focus on antibody based cancer immunotherapies.
•
10:20 – 10:35
Nanoscopy Revolution: Unlocking Spatial Proteomics at unprecedented resolution
Quentin Lubart, Head of Business Development, Abbelight
Understanding how therapeutic antibodies interact with their targets at the nanoscale is essential for the development of next-generation biologics. We will present quantitative super-resolution nanoscopy assays developed at Abbelight to measure receptor clustering at the plasma membrane and to characterize antibody internalization and intracellular trafficking with nanometric resolution. These approaches provide robust, quantitative readouts that complement conventional imaging methods and support the evaluation of antibody mechanism of action, target engagement and candidate selection across a broad range of therapeutic modalities.
Quentin Lubart, Head of Business Development, Abbelight
Understanding how therapeutic antibodies interact with their targets at the nanoscale is essential for the development of next-generation biologics. We will present quantitative super-resolution nanoscopy assays developed at Abbelight to measure receptor clustering at the plasma membrane and to characterize antibody internalization and intracellular trafficking with nanometric resolution. These approaches provide robust, quantitative readouts that complement conventional imaging methods and support the evaluation of antibody mechanism of action, target engagement and candidate selection across a broad range of therapeutic modalities.
•
10:35 – 11:05
Coffee Break & Networking at the Atrium
•
11:05 – 11:40
MAIT Engagers: A New Class of T-Cell Engagers with a Stronger Safety Profile and Larger Therapeutic Window for the Treatment of Cancer
Simon Plyte, Chief Scientific Officer, Biomunex Pharmaceuticals
• MAIT cells are an abundant, tissue and tumor resident, potent cytotoxic CD8 T-cell subset with an invariant T cell receptor.
• MAIT engagers are bispecific antibodies that uniquely bridge MAIT cells to cancer cells via a tumor antigen and induce MAIT-mediated cytotoxicity.
• MAIT engagers are safer than CD3 engagers and do not induce cytokine release syndrome, a known clinical toxicity of CD3 engagers.
• MAIT engagers, unlike CD3 engagers, do not activate regulatory T cells, which can dampen cytotoxicity in the tumor microenvironment.
• Taken together, these features of MAIT engagers afford a large therapeutic window.
Simon Plyte, Chief Scientific Officer, Biomunex Pharmaceuticals
• MAIT cells are an abundant, tissue and tumor resident, potent cytotoxic CD8 T-cell subset with an invariant T cell receptor.
• MAIT engagers are bispecific antibodies that uniquely bridge MAIT cells to cancer cells via a tumor antigen and induce MAIT-mediated cytotoxicity.
• MAIT engagers are safer than CD3 engagers and do not induce cytokine release syndrome, a known clinical toxicity of CD3 engagers.
• MAIT engagers, unlike CD3 engagers, do not activate regulatory T cells, which can dampen cytotoxicity in the tumor microenvironment.
• Taken together, these features of MAIT engagers afford a large therapeutic window.
•
11:40 – 12:15
AI-Driven Protein Design for Next-Generation Biologics and Biotherapies
Sophie Barbe, Co-founder, Amineo
Amineo is a biotechnology start-up specializing in AI-powered protein design, from the multi-criteria optimization of existing proteins to the de novo generation of novel, tailor-made proteins. Its platform combines generative and hybrid artificial intelligence, automated reasoning, robotics-inspired algorithms, and physics-based molecular modeling to design antibodies, nanobodies, mini-proteins, and other protein-based molecules. The design process jointly considers key properties such as affinity, specificity, stability, cross-reactivity, manufacturability, and developability. The presentation will introduce the underlying strategy and illustrate representative applications of AI-driven de novo binder design, with a particular focus on nanobodies and mini-binders. These examples will show how such approaches can expand the repertoire of therapeutic binders, shorten discovery timelines, and facilitate the development of innovative biologics and diagnostics.
Sophie Barbe, Co-founder, Amineo
Amineo is a biotechnology start-up specializing in AI-powered protein design, from the multi-criteria optimization of existing proteins to the de novo generation of novel, tailor-made proteins. Its platform combines generative and hybrid artificial intelligence, automated reasoning, robotics-inspired algorithms, and physics-based molecular modeling to design antibodies, nanobodies, mini-proteins, and other protein-based molecules. The design process jointly considers key properties such as affinity, specificity, stability, cross-reactivity, manufacturability, and developability. The presentation will introduce the underlying strategy and illustrate representative applications of AI-driven de novo binder design, with a particular focus on nanobodies and mini-binders. These examples will show how such approaches can expand the repertoire of therapeutic binders, shorten discovery timelines, and facilitate the development of innovative biologics and diagnostics.
•
12:15 – 12:50
De-Risking Therapeutic Antibody Development: Biological Tools in the Age of AI
Jacques Fieschi-Méric, Chief Scientific Officer, MImAbs
MImAbs delivers end-to-end antibody discovery and ADC development through a unique combination of single B-cell functional screening (Beacon®), high-throughput bioproduction, and expert conjugation chemistry. Their function-first approach enables direct selection of therapeutic candidates based on native cell behaviour, affinity, internalization, neutralization, and cross-reactivity in a single workflow. Jacques will share how predictive computational tools offer growing opportunities to improve candidate pre-filtering and conjugation rationalization, compressing timelines without compromising biological relevance. As AI reshapes antibody discovery, MImAbs is positioned at the interface: combining irreplaceable biological insight with emerging algorithmic strategies to accelerate therapeutic antibody development.
Jacques Fieschi-Méric, Chief Scientific Officer, MImAbs
MImAbs delivers end-to-end antibody discovery and ADC development through a unique combination of single B-cell functional screening (Beacon®), high-throughput bioproduction, and expert conjugation chemistry. Their function-first approach enables direct selection of therapeutic candidates based on native cell behaviour, affinity, internalization, neutralization, and cross-reactivity in a single workflow. Jacques will share how predictive computational tools offer growing opportunities to improve candidate pre-filtering and conjugation rationalization, compressing timelines without compromising biological relevance. As AI reshapes antibody discovery, MImAbs is positioned at the interface: combining irreplaceable biological insight with emerging algorithmic strategies to accelerate therapeutic antibody development.
•
12:50 – 14:00
Networking Lunch at the Atrium
•
14:00 – 14:35
Egle Tx Strategy: Leveraging IL-2 Muteins for Treg Modulation in Cancer and Autoimmunity
Aurélie Auguste, Head of Translational Medicine, Egle Therapeutics
Egle Therapeutics leverages regulatory T-cell (Treg) biology to develop differentiated immunotherapies across cancer and autoimmunity. In oncology, EGL-001, a CTLA-4-targeting antibody fused to a CD25-biased IL-2 antagonist mutein, selectively starves and depletes Tregs within the tumor microenvironment, restoring antitumor immunity and enhancing checkpoint inhibitor activity. In contrast, in autoimmunity, EGL-003, an Fc-fused, CD25-biased IL-2 agonist mutein, selectively expands and activates functional Tregs while minimizing conventional T-cell and NK-cell activation, thereby restoring immune tolerance. Together, EGL-001 and EGL-003 highlight Egle’s complementary strategy: Treg depletion in cancer versus selective Treg expansion in autoimmunity, addressing opposing immune dysregulations through tailored IL-2 modulation.
Aurélie Auguste, Head of Translational Medicine, Egle Therapeutics
Egle Therapeutics leverages regulatory T-cell (Treg) biology to develop differentiated immunotherapies across cancer and autoimmunity. In oncology, EGL-001, a CTLA-4-targeting antibody fused to a CD25-biased IL-2 antagonist mutein, selectively starves and depletes Tregs within the tumor microenvironment, restoring antitumor immunity and enhancing checkpoint inhibitor activity. In contrast, in autoimmunity, EGL-003, an Fc-fused, CD25-biased IL-2 agonist mutein, selectively expands and activates functional Tregs while minimizing conventional T-cell and NK-cell activation, thereby restoring immune tolerance. Together, EGL-001 and EGL-003 highlight Egle’s complementary strategy: Treg depletion in cancer versus selective Treg expansion in autoimmunity, addressing opposing immune dysregulations through tailored IL-2 modulation.
•
14:35 – 15:10
ADCs: New Modalities
Florence Lhospice, Founder, Kesten Biotech
ADCs: new modalities, pros and cons.
Florence Lhospice, Founder, Kesten Biotech
ADCs: new modalities, pros and cons.
•
15:10 – 15:45
Degrader-Antibody Conjugates: The Next Wave in Targeted Oncology
Didier Roche, Chief Scientific Officer, Edelris
Degrader-Antibody Conjugates (DACs) represent an emerging therapeutic modality that fuses the targeted delivery of antibody-drug conjugates with the catalytic power of targeted protein degradation. By linking a monoclonal antibody to a small-molecule degrader via a cleavable linker, DACs aim to overcome the cell-permeability limits of PROTACs while widening the therapeutic window of conventional ADCs. This talk covers the DAC mechanism of action, how it compares to ADCs and PROTACs, current clinical and industry momentum, key technical hurdles, and future applications beyond oncology.
Didier Roche, Chief Scientific Officer, Edelris
Degrader-Antibody Conjugates (DACs) represent an emerging therapeutic modality that fuses the targeted delivery of antibody-drug conjugates with the catalytic power of targeted protein degradation. By linking a monoclonal antibody to a small-molecule degrader via a cleavable linker, DACs aim to overcome the cell-permeability limits of PROTACs while widening the therapeutic window of conventional ADCs. This talk covers the DAC mechanism of action, how it compares to ADCs and PROTACs, current clinical and industry momentum, key technical hurdles, and future applications beyond oncology.
•
15:45 – 16:10
Coffee Break & Networking at the Atrium
•
16:10 – 16:45
Radioimmunoconjugates for Theranostic Applications
Franck Denat, Professor, ICMUB (CNRS)
Nuclear medicine has become a powerful tool in the area of personalized care, especially in oncology. Labeling molecules with gamma or positron emitters enables tumor imaging by SPECT and PET, respectively, whereas labeling the same molecules with alpha or beta-emitting radionuclides allows targeted radionuclide therapy. “See what you treat and treat what you see” is made possible through the use of radiotheranostic approaches. Antibodies and fragments are particularly valuable targeting agents. Chemistry is central to advancing radioimmunoconjugates, through the development of efficient radiometal chelators, multivalent platforms, and innovative bioconjugation strategies.
Franck Denat, Professor, ICMUB (CNRS)
Nuclear medicine has become a powerful tool in the area of personalized care, especially in oncology. Labeling molecules with gamma or positron emitters enables tumor imaging by SPECT and PET, respectively, whereas labeling the same molecules with alpha or beta-emitting radionuclides allows targeted radionuclide therapy. “See what you treat and treat what you see” is made possible through the use of radiotheranostic approaches. Antibodies and fragments are particularly valuable targeting agents. Chemistry is central to advancing radioimmunoconjugates, through the development of efficient radiometal chelators, multivalent platforms, and innovative bioconjugation strategies.
•
16:45 – 17:30
Panel Discussion – The Future of Antibody Innovation
Moderated by Jérôme Galon, Director of Laboratory, Inserm
Moderated by Jérôme Galon, Director of Laboratory, Inserm
•
17:30 – 17:35
Closing Address
Jacques Fieschi-Méric, Chief Scientific Officer, MImAbs
Jacques Fieschi-Méric, Chief Scientific Officer, MImAbs
•
17:40 – 19:00
Networking Cocktail Reception at the Atrium
Our sponsor
